Latest News and Press Releases

BRISBANE, Calif., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today...

BRISBANE, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today...

BRISBANE, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today...

Transforming company with focus and commitment on neglected and rare diseases Continue to expect New Drug Application (NDA) submission for benznidazole in Chagas disease to FDA in first quarter 2018 ...

BRISBANE, Calif., July 12, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTCQB:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...

BRISBANE, Calif., July 11, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTCQB:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...

Open IND is a significant step to advancing the benznidazole development programCompany remains on track to submit a New Drug Application in the first quarter of 2018 BRISBANE, Calif., June 27,...

BRISBANE, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTCQB: KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...

BRISBANE, Calif., May 31, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...

BRISBANE, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...